Literature DB >> 11703370

Dexamethasone impairs pulmonary defence against Pseudomonas aeruginosa through suppressing iNOS gene expression and peroxynitrite production in mice.

S Satoh1, K Oishi, A Iwagaki, M Senba, T Akaike, M Akiyama, N Mukaida, K M Atsushima, T Nagatake.   

Abstract

To elucidate the in vivo mechanisms involved in the impairment in pulmonary defence as the result of treatment with glucocorticoids, we established fatal pneumonia with bacteraemia in dexamethasone (DEX)-treated mice by means of an intratracheal challenge of Pseudomonas aeruginosa. An increased neutrophil influx was observed in bronchoalveolar lavage (BAL) fluids from both untreated and DEX-treated mice. The complete suppression of an inducible isoform of nitric oxide synthase (iNOS) mRNA expression and tumour necrosis factor alpha (TNF-alpha) production during the early phase of pneumonia, but not CXC chemokine production, were found in the case of the DEX-treated mice. An immunohistochemical study with a specific antibody also revealed negative staining for nitrotyrosine in the lung tissue of DEX-treated mice, while the formation of nitrotyrosine, which indirectly indicates the generation of peroxynitrite with a potent bactericidal activity, was detected clearly in the bronchial epithelium as well as alveolar phagocytic cells of lung tissue from untreated mice. Furthermore, an intraperitoneal administration of S-methyl-isothiourea (SMT), a potent inhibitor of NOS, significantly decreased the survival and increased bacterial density in the case of untreated mice. In contrast, no significant effects on the survival and bacterial density in the lung and blood were found as the result of treatment with SMT in DEX-treated mice. Collectively, a complete repression of iNOS gene expression and a lack of the generation of peroxynitrite as well as an inhibition of TNF-alpha production in the lung appeared to be responsible for the progression of the fatal pneumonia due to P. aeruginosa in DEX-treated mice.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11703370      PMCID: PMC1906189          DOI: 10.1046/j.1365-2249.2001.01656.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  37 in total

Review 1.  Combination of inhaled corticosteroids plus other medications in the management of moderate to severe persistent asthma.

Authors:  P Fireman
Journal:  Allergy Asthma Proc       Date:  2000 Sep-Oct       Impact factor: 2.587

2.  Neutrophils enhance expression of inducible nitric oxide synthase in human normal but not cystic fibrosis bronchial epithelial cells.

Authors:  Q H Meng; J M Polak; A J Edgar; M R Chacon; T J Evans; D C Gruenert; A E Bishop
Journal:  J Pathol       Date:  2000-02       Impact factor: 7.996

Review 3.  Mechanisms of glucocorticoid action on immune processes.

Authors:  J E Parrillo; A S Fauci
Journal:  Annu Rev Pharmacol Toxicol       Date:  1979       Impact factor: 13.820

4.  Expression of chemokine genes in murine macrophages infected with Orientia tsutsugamushi.

Authors:  N H Cho; S Y Seong; M S Huh; T H Han; Y S Koh; M S Choi; I S Kim
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

5.  Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival.

Authors:  K R Flaherty; G B Toews; J P Lynch; E A Kazerooni; B H Gross; R L Strawderman; K Hariharan; A Flint; F J Martinez
Journal:  Am J Med       Date:  2001-03       Impact factor: 4.965

6.  Role of cytokine-induced neutrophil chemoattractant-2 (CINC-2) alpha in a rat model of chronic bronchopulmonary infections with Pseudomonas aeruginosa.

Authors:  H Amano; K Oishi; F Sonoda; M Senba; A Wada; H Nakagawa; T Nagatake
Journal:  Cytokine       Date:  2000-11       Impact factor: 3.861

7.  Pathogenesis of Pseudomonas aeruginosa pneumonia during immunosuppression.

Authors:  J E Pennington; M G Ehrie
Journal:  J Infect Dis       Date:  1978-06       Impact factor: 5.226

8.  Innate lung defenses and compromised Pseudomonas aeruginosa clearance in the malnourished mouse model of respiratory infections in cystic fibrosis.

Authors:  H Yu; S Z Nasr; V Deretic
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

9.  Lung-specific transgenic expression of KC enhances resistance to Klebsiella pneumoniae in mice.

Authors:  W C Tsai; R M Strieter; J M Wilkowski; K A Bucknell; M D Burdick; S A Lira; T J Standiford
Journal:  J Immunol       Date:  1998-09-01       Impact factor: 5.422

10.  Physiologic regulation of postovulatory neutrophil migration into vagina in mice by a C-X-C chemokine(s).

Authors:  Y Sonoda; N Mukaida; J B Wang; M Shimada-Hiratsuka; M Naito; T Kasahara; A Harada; M Inoue; K Matsushima
Journal:  J Immunol       Date:  1998-06-15       Impact factor: 5.422

View more
  12 in total

Review 1.  Innate immune responses to Pseudomonas aeruginosa infection.

Authors:  Elise G Lavoie; Tamding Wangdi; Barbara I Kazmierczak
Journal:  Microbes Infect       Date:  2011-08-02       Impact factor: 2.700

2.  Dexamethasone suppresses interleukin-22 associated with bacterial infection in vitro and in vivo.

Authors:  E Ziesché; P Scheiermann; M Bachmann; C D Sadik; C Hofstetter; B Zwissler; J Pfeilschifter; H Mühl
Journal:  Clin Exp Immunol       Date:  2009-09       Impact factor: 4.330

3.  Inflammatory mechanisms underlying the rat pulmonary neutrophil influx induced by airway exposure to staphylococcal enterotoxin type A.

Authors:  Ivani A Desouza; Carla F Franco-Penteado; Enilton A Camargo; Carmen S P Lima; Simone A Teixeira; Marcelo N Muscará; Gilberto De Nucci; Edson Antunes
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

4.  Effects of nitric oxide on Pseudomonas aeruginosa infection of epithelial cells from a human respiratory cell line derived from a patient with cystic fibrosis.

Authors:  Katharine E A Darling; Thomas J Evans
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

5.  Kinase suppressor of Ras-1 protects against pulmonary Pseudomonas aeruginosa infections.

Authors:  Yang Zhang; Xiang Li; Alexander Carpinteiro; Jeremy A Goettel; Matthias Soddemann; Erich Gulbins
Journal:  Nat Med       Date:  2011-02-06       Impact factor: 53.440

6.  Fourteen-member macrolides suppress interleukin-8 production but do not promote apoptosis of activated neutrophils.

Authors:  Yoshiko Tsuchihashi; Kazunori Oishi; Hiroyuki Yoshimine; Shoichi Suzuki; Atsushi Kumatori; Toshiaki Sunazuka; Satoshi Omura; Kouji Matsushima; Tsuyoshi Nagatake
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

7.  Ohr plays a central role in bacterial responses against fatty acid hydroperoxides and peroxynitrite.

Authors:  Thiago G P Alegria; Diogo A Meireles; José R R Cussiol; Martín Hugo; Madia Trujillo; Marcos Antonio de Oliveira; Sayuri Miyamoto; Raphael F Queiroz; Napoleão Fonseca Valadares; Richard C Garratt; Rafael Radi; Paolo Di Mascio; Ohara Augusto; Luis E S Netto
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-27       Impact factor: 11.205

8.  Fourteen-member macrolides promote the phosphatidylserine receptor-dependent phagocytosis of apoptotic neutrophils by alveolar macrophages.

Authors:  Takeshi Yamaryo; Kazunori Oishi; Hiroyuki Yoshimine; Yoshiko Tsuchihashi; Kouji Matsushima; Tsuyoshi Nagatake
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

9.  Inhaled fluticasone propionate impairs pulmonary clearance of Klebsiella pneumoniae in mice.

Authors:  Craig M Patterson; Richard L Morrison; Alain D'Souza; Xu S Teng; Kyle I Happel
Journal:  Respir Res       Date:  2012-05-31

10.  Treatment of infected lungs by ex vivo perfusion with high dose antibiotics and autotransplantation: A pilot study in pigs.

Authors:  Norman Zinne; Marcus Krueger; Doris Hoeltig; Burkhard Tuemmler; Erin C Boyle; Christian Biancosino; Klaus Hoeffler; Peter Braubach; Taufiek K Rajab; Anatol Ciubotaru; Judith Rohde; Karl-Heinz Waldmann; Axel Haverich
Journal:  PLoS One       Date:  2018-03-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.